Cell Technology, Inc.

TORONTO, Sept. 18, 2023 /PRNewswire/ - CELL Technologies Inc. is pleased to announce the award of a No Objection Letter (NOL) from Health Canada to launch the first ever pivotal stem cell program in pain and Osteoarthritis in the world. ​ "I want to congratulate all Canadians. To have the first approved pivotal stem cell program in the world being launched in Canada, is a huge victory for all of us," says CEO Dr. Riam Shammaa. "Now patients across Canada have access to evidence-based and regulatory validated stem cells," says Dr. Shammaa. "I want to thank the team of CELL for their great work and dedication over the years to get to this huge success," says Shammaa. The program now allows patients with pain conditions to enroll in evidence-based and regulatory validated stem cell treatment across all Canada. "The No Objection Letter is a significant seal of approval from Health Canada," says Dr. Gregory Murphy, Chief Medical Officer of CELL. "It means that the regulators have reviewed and approved the efficacy of our scientific and clinical data. It also means that the regulators have reviewed and validated the safety of our processing and manufacturing, and they green light enrolling patients in the first evidence-based stem cell pivotal program in the world," says Dr. Murphy. Based on the breakthrough data and the positive regulatory approval, CELL is now preparing to the FDA to get a similar approval in the US. About CELL CELL is a clinical stage biotech company pioneering stem cell therapy in pain medicine and inflammatory conditions, CELL's platform is based on proprietary technology in both autologous and allogeneic programs with more than 10 years of research in the field of cell therapy. CELL is the leader in stem cell therapy in North America and aims to become the first provider of stem cells for regenerative medicine globally. For information and for patients looking to access the stem cell program: info@celltechnologies.net ​ View original content to download multimedia: SOURCE Cell Technologies Inc.

TORONTO, April 26, 2023 /PRNewswire/ - On the heel of the regulatory meeting with Health Canada on March 31st 2023, CELL Technologies Inc. announces the submission of the clinical data of its stem cell program in pain for Health Canada approval. CELL is aiming to become the first regulatory approved stem cell provider in North America. CELL submitted clinical data of 3 studies in Arthritis, degenerative disc disease and back pain. The program will allow patients with pain conditions to access evidence-based and regulatory approved stem cell procedures across all Canada. "This is a great milestone in our quest to give suffering patients access to evidence-based, regulatory approved stem cells in Canada" says CEO Dr. Riam Shammaa, "Patients don't have to suffer anymore without access to life changing procedures, nor do they have to incur heavy costs to travel abroad and get unvalidated treatment" says Dr. Shammaa. "After more than 10 years of research, we are pleased to announce that we are one step closer to a national approval" says Shammaa. CELL has successfully conducted early and comparative clinical studies at the Canadian Centre for Regenerative Therapy. "Our published clinical studies showed robust safety and efficacy with 60% reduction in pain in arthritis, more than 85% success in repairing degenerated discs in the lumbar spine and more than 60% of patients stopping opioids after treatment" says Dr. Gregory Murphy, Chief Medical Officer of CELL. CELL is preparing to file an application to launch a national pivotal clinical program by Q3 2023 About CELL CELL is a clinical stage biotech company pioneering stem cell therapy in pain medicine and inflammatory conditions, CELL's platform is based on proprietary technology in both autologous and allogeneic programs with more than 10 years of research in the field of cell therapy. SOURCE Cell Technologies Inc.